Intracranial Pressure Monitoring Systems

Quick Answer

Intracranial pressure (ICP) monitoring is a cornerstone of neurocritical care, enabling real-time assessment of intracranial dynamics and guiding therapeutic interventions. The Monro-Kellie doctrine states that the cranium is a fixed volume containing brain (~80%), blood (~10%), and CSF (~10%); an increase in one compartment must be compensated by a decrease in another or ICP will rise. Normal ICP is 7-15 mmHg in adults. ICP waveforms (P1, P2, P3 waves) reflect cardiac cycle transmission; when P2 > P1, intracranial compliance is reduced. The gold standard for ICP monitoring is the external ventricular drain (EVD), which allows both measurement and therapeutic CSF drainage. Intraparenchymal monitors (Codman, Camino, Raumedic) are alternatives when ventricular cannulation fails. Cerebral perfusion pressure (CPP) = MAP - ICP; the Brain Trauma Foundation (BTF) 2024 recommends maintaining CPP 60-70 mmHg and treating ICP >22 mmHg. EVD management requires sterile technique, leveling at the tragus, and monitoring for complications including ventriculitis (5-20%), hemorrhage (1-2%), and catheter malposition.

---

CICM Exam Focus

What Examiners Expect

Second Part Written (SAQ):

Common SAQ stems:

• "Describe the Monro-Kellie doctrine and its implications for intracranial pressure management."
• "Compare and contrast the different methods of intracranial pressure monitoring. Discuss the advantages and disadvantages of each."
• "A patient with severe traumatic brain injury has an ICP of 28 mmHg despite Tier 1 therapies. Outline your escalation strategy."
• "Discuss the interpretation of ICP waveforms and their clinical significance."
• "Describe the complications of external ventricular drainage and their management."
• "A patient with an EVD develops fever and CSF pleocytosis. Outline your approach to diagnosis and management."

SAQ scoring expectations:

• Systematic explanation of intracranial physiology (Monro-Kellie)
• Comprehensive comparison of monitoring modalities
• Evidence-based ICP thresholds and CPP targets (BTF 2024)
• Tiered approach to ICP management
• Recognition and management of complications
• Understanding of BEST-TRIP trial limitations

Second Part Hot Case:

Typical presentations:

• Severe TBI patient with EVD in situ and elevated ICP
• Post-craniotomy patient with intracranial hypertension
• Subarachnoid hemorrhage with hydrocephalus requiring EVD
• Neurosurgical patient with ICP waveform changes
• Patient with EVD-related ventriculitis

Examiners assess:

• Systematic assessment of ICP trends and waveforms
• Integration with multimodality monitoring (PbtO2, SjvO2, EEG)
• Recognition of herniation syndromes
• Safe EVD management and troubleshooting
• Evidence-based escalation pathway
• Communication with neurosurgical team

Second Part Viva:

Expected discussion areas:

• Monro-Kellie doctrine and intracranial compliance
• ICP waveform interpretation (P1, P2, P3)
• Comparison of EVD vs intraparenchymal monitors
• BTF guidelines (threshold changes, CPP targets)
• Tiered ICP management (Tier 0, 1, 2, 3)
• BEST-TRIP trial interpretation
• Multimodality monitoring (PbtO2, microdialysis)
• Osmotherapy (mannitol vs hypertonic saline)
• Decompressive craniectomy evidence

Examiner expectations:

• Fluent discussion of intracranial physiology
• Evidence-based practice citing BTF 2024
• Safe, consultant-level ICP management
• Understanding of monitoring limitations
• Integration with neurosurgical management
• Knowledge of emerging monitoring modalities

Common Mistakes

• Confusing CPP calculation (CPP = MAP - ICP, not SAP - ICP)
• Using outdated ICP threshold of 20 mmHg (BTF 2024 uses 22 mmHg)
• Not understanding ICP waveform morphology
• Failing to consider EVD leveling and zeroing errors
• Over-interpreting BEST-TRIP as evidence against ICP monitoring
• Aggressive CPP augmentation >70 mmHg (increases ARDS risk)
• Not recognizing compliance changes from waveform morphology
• Forgetting to rule out systemic causes of ICP elevation (hypoxia, hypercapnia, fever)

---

Key Points

Must-Know Facts

1. Monro-Kellie Doctrine: The cranium is a rigid box with fixed volume (~1,400-1,700 mL); the sum of brain (80%), blood (10%), and CSF (10%) volumes is constant. Volume compensation occurs through CSF displacement and venous blood reduction until exhausted.

2. Normal ICP Values: Adults 7-15 mmHg (lying); children 3-7 mmHg; infants 1.5-6 mmHg. ICP >22 mmHg requires treatment (BTF 2024, previously >20 mmHg).

3. Cerebral Perfusion Pressure: CPP = MAP - ICP. Target 60-70 mmHg (BTF 2024). Lund Concept targets CPP 50-60 mmHg. CPP <50 mmHg associated with increased mortality; CPP >70 mmHg increases ARDS risk.

4. ICP Waveforms: Three components reflecting cardiac cycle - P1 (percussion wave, arterial pulsation), P2 (tidal wave, intracranial compliance), P3 (dicrotic wave, venous pulsation). Normal: P1 > P2 > P3. Reduced compliance: P2 > P1.

5. Lundberg Waves: A waves (plateau waves, 50-100 mmHg for 5-20 min, pathological, indicate exhausted compliance), B waves (1-2/min, pressure oscillation 20-50 mmHg, may be physiological), C waves (4-8/min, small amplitude, related to arterial waveform).

6. EVD Gold Standard: Measures global ICP, allows therapeutic CSF drainage, calibration possible. Zero at tragus (external auditory meatus). Complications: ventriculitis 5-20%, hemorrhage 1-2%, malposition.

7. Intraparenchymal Monitors: Measure local pressure, cannot drain CSF, prone to drift (0.5-3 mmHg/day). Types: Codman (strain gauge), Camino (fiberoptic), Raumedic (piezoelectric). Insertion depth: 2-3 cm into brain parenchyma.

8. BTF 2024 Guidelines: Treat ICP >22 mmHg (Level IIB), target CPP 60-70 mmHg, avoid CPP <50 mmHg (Level III) and >70 mmHg (Level IIB, risk of ARDS).

9. BEST-TRIP Trial: No mortality difference between ICP monitor-guided vs clinical/imaging-guided therapy in TBI. Does NOT mean ICP monitoring is useless - both arms received aggressive ICP therapy. Highlights importance of clinical assessment.

10. Tiered ICP Management: Tier 0 (prevent rises: head elevation, sedation, temperature control), Tier 1 (EVD drainage, sedation optimization, osmotherapy), Tier 2 (moderate hyperventilation, second-line osmotherapy, neuromuscular blockade), Tier 3 (decompressive craniectomy, barbiturate coma, therapeutic hypothermia).

Memory Aids

MONRO - Monro-Kellie Compartments:

• Matter (brain parenchyma ~80%)
• Occluded (blood ~10%)
• Neutralized (CSF ~10%)
• Rigid skull
• Outlet via foramen magnum

WAVEFORM - ICP Waveform Analysis:

• Watch for P2 > P1 (poor compliance)
• A-waves are Alarming (plateau waves)
• Verify transducer level (tragus)
• Evaluate trends, not single values
• Frequency of B-waves
• Oscillation amplitude
• Recognize dicrotic notch (P3)
• Mean ICP more important than peaks

DRAIN - EVD Complications:

• Disconnection/displacement
• Ruptured (hemorrhage)
• Air in system
• Infection (ventriculitis)
• Not draining (blockage)

---

Definition & Epidemiology

Definition

Intracranial pressure (ICP) is the pressure within the cranial cavity, measured in millimeters of mercury (mmHg) or centimeters of water (cmH2O; 1 mmHg = 1.36 cmH2O). ICP reflects the dynamic equilibrium between the three intracranial compartments (brain, blood, CSF) within the rigid cranial vault.

ICP monitoring refers to the continuous or intermittent measurement of intracranial pressure using invasive or non-invasive techniques to guide management of intracranial hypertension.

Classification of ICP Monitoring Methods:

Epidemiology

International Data:

• Severe traumatic brain injury (GCS ≤8): 10-15 per 100,000 population annually (PMID: 27654279)
• ICP monitoring inserted in 30-50% of severe TBI patients in developed countries
• Intracranial hypertension (ICP >22 mmHg) occurs in 50-75% of severe TBI patients (PMID: 26413143)
• Sustained ICP >20 mmHg for >5 days associated with 85% mortality (PMID: 1990956)

Australian/NZ Data (ANZICS APD):

• Severe TBI ICU admissions: 3-4 per 100,000 annually
• ICP monitoring utilization: 60-70% of severe TBI in tertiary neurotrauma centers
• EVD vs intraparenchymal: approximately 60:40 split in Australian practice
• Median ICP monitoring duration: 5-7 days
• Ventriculitis rate: 8-12% in Australian cohorts (PMID: 28234143)

High-Risk Populations:

• Aboriginal and Torres Strait Islander peoples: 2-3× higher rates of traumatic brain injury; associated with remote trauma, assault, and road traffic incidents; delayed access to neurosurgical care (PMID: 26413143)
• Māori: 1.5-2× higher TBI rates; higher severity at presentation
• Remote/rural populations: Delayed retrieval, longer time to neurosurgical intervention, higher acuity at transfer

Mortality by ICP:

• ICP <20 mmHg: 15-20% mortality
• ICP 20-40 mmHg: 40-60% mortality
• ICP >40 mmHg: 80-90% mortality (PMID: 1990956)

Outcomes:

• Favorable outcome (GOS 4-5) with aggressive ICP management: 35-50%
• Mortality in severe TBI: 30-40% overall
• Functional independence at 6 months: 40-50% of survivors
• Post-craniectomy syndrome: 10-20% of decompressive craniectomy patients

---

Applied Basic Sciences

This section bridges First Part basic sciences with Second Part clinical practice

The Monro-Kellie Doctrine

Historical Context: The Monro-Kellie doctrine, first described by Alexander Monro (1783) and refined by George Kellie (1824), is the fundamental principle underlying intracranial pressure dynamics (PMID: 16882993).

The Doctrine States: The cranium is a rigid container with a fixed total volume. The sum of volumes of brain, cerebrospinal fluid, and intracranial blood is constant. An increase in any one component must be compensated by an equal decrease in another, or intracranial pressure will rise.

Intracranial Compartments:

Compensatory Mechanisms:

1. CSF displacement (most immediate):

   • CSF displaced from intracranial to spinal subarachnoid space
   • Reduced CSF production by choroid plexus
   • Increased CSF absorption at arachnoid granulations
   • Compensates for ~100-150 mL volume increase

2. Venous blood displacement:

   • Compression of bridging veins and dural sinuses
   • Reduction of intracranial venous blood volume
   • More limited capacity than CSF displacement

3. Brain tissue compression (minimal):

   • Extracellular fluid shifts
   • Cell volume reduction (aquaporin-mediated)
   • Very limited capacity

Intracranial Compliance:

Compliance (C) = ΔV / ΔP (change in volume per unit change in pressure)

The pressure-volume curve is exponential, not linear:

• Initially flat: High compliance, volume increases with minimal pressure change
• "Knee" of curve: Compensation exhausted
• Steep portion: Low compliance, small volume increases cause large pressure increases

Elastance (inverse of compliance) = ΔP / ΔV

• Normal intracranial elastance: 0.1-0.4 mmHg/mL
• Elevated elastance indicates reduced compliance

Intracranial Pressure Dynamics

Normal ICP Values:

Factors Affecting ICP:

Physiological:

• Arterial blood pressure (autoregulation)
• Venous pressure (jugular venous, intrathoracic)
• PaCO2 (cerebrovascular reactivity)
• PaO2 (hypoxia causes vasodilation when <50 mmHg)
• Body position (head elevation reduces ICP)

Pathological:

• Mass lesions (tumors, hematomas, abscesses)
• Cerebral edema (cytotoxic, vasogenic, hydrostatic)
• Hydrocephalus (obstructive or communicating)
• Increased cerebral blood volume (hyperemia)
• Venous outflow obstruction

ICP Waveform Analysis

Components of the ICP Waveform (PMID: 29628853):

The ICP waveform is a modified arterial waveform transmitted through the intracranial contents:

Clinical Interpretation:

Lundberg Waves (PMID: 5093859):

Nils Lundberg described three types of slow ICP oscillations:

• cerebral vasodilation, impaired autoregulation | | B waves | 0.5-2/min | 10-20 mmHg | 30 sec - 2 min | Respiratory/vasomotor origin, may be physiological | | C waves | 4-8/min | <10 mmHg | Continuous | Traube-Hering-Mayer waves, arterial origin |

A Waves (Plateau Waves):

• Most clinically significant
• Represent cyclical cerebrovascular dysregulation
• Mechanism: ICP rises → CPP falls → autoregulatory vasodilation → increased CBV → further ICP rise
• Require immediate intervention

Cerebral Perfusion Pressure

Definition and Calculation:

CPP = MAP - ICP (or MAP - CVP if CVP > ICP)

Where:

• MAP = Mean arterial pressure (measured at head level)
• ICP = Intracranial pressure
• CVP = Central venous pressure (rarely dominant)

Transducer Leveling:

• MAP transducer must be leveled at the tragus (external auditory meatus) to accurately reflect cerebral perfusion
• If MAP measured at heart level in supine patient, no adjustment needed
• If patient head-elevated, MAP at head level is lower than at heart by ~0.77 mmHg per cm elevation

CPP Targets (BTF 2024) (PMID: 27654279):

Rationale for Upper CPP Limit:

• Robertson et al. (PMID: 9887178): CPP augmentation >70 mmHg associated with 5× increased ARDS risk
• Mechanism: Vasopressor-induced pulmonary capillary leak, fluid overload

Cerebral Autoregulation:

Normal autoregulation maintains constant CBF across MAP 50-150 mmHg (CPP 50-150 mmHg):

• Below lower limit: CBF falls passively with CPP (ischemia risk)
• Above upper limit: CBF rises passively with CPP (hyperemia, edema risk)
• In TBI: Autoregulation often impaired, CBF becomes pressure-passive

Pressure Reactivity Index (PRx) (PMID: 12169678):

• Correlation coefficient between slow waves of ABP and ICP
• PRx < 0: Intact autoregulation (pressure rise → vasoconstriction → ICP falls)
• PRx > 0.3: Impaired autoregulation (pressure rise → passive ICP rise)
• Optimal CPP (CPPopt) identified as CPP at lowest PRx

CSF Dynamics

CSF Production:

• Rate: 0.3-0.4 mL/min (450-500 mL/day)
• Source: Choroid plexus (70%), ependyma, brain parenchyma (30%)
• Mechanism: Active secretion (Na⁺/K⁺-ATPase, carbonic anhydrase)
• Total CSF volume: 120-150 mL (25% intracranial, 75% spinal)

CSF Circulation: Lateral ventricles → Foramen of Monro → Third ventricle → Cerebral aqueduct → Fourth ventricle → Foramina of Luschka and Magendie → Subarachnoid space → Arachnoid granulations → Dural venous sinuses

CSF Absorption:

• Primary: Arachnoid granulations (pressure-dependent)
• Secondary: Lymphatic drainage, transependymal absorption
• Absorption increases with elevated ICP

Hydrocephalus Classification:

---

Monitoring Devices

External Ventricular Drain (EVD)

The Gold Standard:

The EVD remains the gold standard for ICP monitoring because it provides:

1. Accurate global ICP measurement
2. Therapeutic CSF drainage capability
3. Re-calibration possible (unlike parenchymal monitors)
4. Access for intrathecal drug administration
5. CSF sampling for analysis

Anatomy and Insertion:

Kocher's Point (frontal approach, most common):

• Location: 11 cm posterior to nasion, 3 cm lateral to midline (at mid-pupillary line)
• Trajectory: Perpendicular to skull, aimed at medial canthus of ipsilateral eye in coronal plane, toward external auditory meatus in sagittal plane
• Target: Frontal horn of lateral ventricle (ipsilateral, usually non-dominant hemisphere)
• Depth: Typically 5-7 cm from skull surface

Alternative Approaches:

• Keen's point (parieto-occipital): 3 cm above and behind pinna
• Frazier's point (occipital): 6 cm above inion, 4 cm lateral

Technical Specifications:

EVD Management Protocol:

1. Leveling: Zero transducer at tragus (external auditory meatus)
2. Drainage height: Typically 10-20 cmH2O above tragus
3. Open vs closed drainage:
   • Open (continuous): Continuous drainage at set height
   • Closed (intermittent): Drain when ICP exceeds threshold, then clamp
4. Documentation: Hourly ICP, drainage volume, CSF character, waveform quality
5. CSF sampling: Sterile technique, every 3-5 days or if infection suspected

Complications of EVD:

Evidence for Antimicrobial-Impregnated Catheters (PMID: 22935200):

• Rifampicin/minocycline-impregnated catheters reduce ventriculitis by ~45%
• Cost-effective when baseline ventriculitis rate >4%
• BTF does not make strong recommendation (Level III evidence)

Intraparenchymal Monitors

Types of Intraparenchymal Monitors:

Insertion Technique:

• Location: Usually frontal, non-eloquent cortex
• Depth: 2-3 cm into brain parenchyma (white matter)
• Can be inserted through burr hole or bolt system
• No intraoperative calibration possible (factory calibrated)

Advantages:

• Lower infection risk than EVD (~2-5% vs 5-20%)
• Easier insertion, less expertise required
• Suitable when ventricles small/collapsed
• Continuous monitoring without drainage interruption

Disadvantages:

• Cannot drain CSF (major limitation)
• Zero drift: 0.5-3 mmHg per day (PMID: 22935200)
• Cannot recalibrate after insertion
• Measures local, not global pressure (may miss contralateral pathology)
• No CSF sampling possible

Clinical Accuracy (PMID: 22935200):

• Correlation with EVD: r = 0.94-0.98 (good overall)
• Mean difference: 0-2 mmHg initially
• Drift: Clinically significant in 20-30% after 5+ days

Subdural and Epidural Monitors

Subdural Monitors (Subdural Bolt):

• Placed in subdural space via burr hole
• Less accurate than ventricular or parenchymal
• Prone to membrane formation and dampening
• Historical use, now rarely used

Epidural Monitors:

• Placed between skull and dura
• Least accurate (dura acts as buffer)
• Essentially abandoned in clinical practice
• Historical interest only

Non-Invasive ICP Estimation

Transcranial Doppler (TCD):

The pulsatility index (PI) correlates with ICP:

• PI = (Systolic velocity - Diastolic velocity) / Mean velocity
• PI > 1.2 suggests elevated ICP (PMID: 24667570)
• Diastolic velocity < 20 cm/s suggests very high ICP
• Sensitivity 89%, Specificity 92% for ICP >20 mmHg

Optic Nerve Sheath Diameter (ONSD) (PMID: 21871441):

• Measured 3 mm behind globe using ultrasound
• ONSD > 5.0-5.7 mm suggests ICP >20 mmHg
• Meta-analysis: Sensitivity 90%, Specificity 85% for elevated ICP
• Quick, non-invasive, but operator-dependent

Pupillometry:

• Automated pupillometers measure pupil reactivity (NPi)
• NPi < 3 associated with elevated ICP and poor prognosis (PMID: 29628853)
• Useful for trending, not absolute ICP measurement

CT Signs of Elevated ICP:

• Effaced basal cisterns (3-4mm normal thickness)
• Midline shift >5 mm
• Compressed sulci
• Hydrocephalus
• Herniation syndromes

Limitations of Non-Invasive Methods:

• Cannot provide continuous monitoring
• Cannot guide titration of therapy
• Insufficient for ICP-directed management
• Role limited to screening, triage, and monitoring trends

---

EVD Management

Insertion Considerations

Indications for EVD Insertion (PMID: 27654279):

Pre-Insertion Checklist:

• Coagulation: INR <1.5, PLT >50-100 × 10⁹/L (PMID: 25320101)
• CT brain review
• Consent (if possible) or emergency consent
• Equipment availability
• Neurosurgical backup

Post-Insertion Care:

1. CT confirmation: Verify catheter position and exclude hemorrhage
2. Leveling: Zero at tragus, document reference point
3. Initial drainage settings: Usually 10-15 cmH2O above tragus
4. ICP target: Maintain ICP <22 mmHg (BTF 2024)
5. CPP target: Maintain CPP 60-70 mmHg

CSF Drainage Strategies

Continuous vs Intermittent Drainage:

Drainage Height Adjustment:

• Higher drainage level = less drainage, higher ICP allowed before drainage
• Lower drainage level = more drainage, risks over-drainage

Over-Drainage Complications:

• Slit ventricle syndrome
• Subdural hematoma (tearing of bridging veins)
• Upward (transtentorial) herniation
• Trapped fourth ventricle
• Intracranial hypotension symptoms (headache, nausea)

Under-Drainage Complications:

• Uncontrolled intracranial hypertension
• Secondary brain injury
• Herniation syndromes

EVD Weaning and Removal

Readiness Criteria:

• ICP consistently <15-20 mmHg for 24-48 hours
• No recent ICP spikes requiring drainage
• Neurological stability
• CT showing resolving pathology
• No evidence of hydrocephalus

Weaning Protocol (PMID: 28234143):

1. Raise drainage height by 5 cm increments
2. Monitor ICP for 24 hours at each level
3. Eventually clamp and monitor for 24-48 hours
4. If ICP remains <20-22 mmHg while clamped, remove EVD
5. Repeat CT to confirm no hydrocephalus before removal

Ventriculoperitoneal Shunt (VPS) Consideration:

• If unable to wean EVD after 10-14 days
• Persistent hydrocephalus requiring CSF diversion
• Shunt-dependent hydrocephalus risk: 10-40% post-SAH, 5-15% post-TBI

Ventriculitis Management

Diagnosis (PMID: 28234143):

Clinical features:

• Fever (may be absent in critically ill)
• Altered consciousness (difficult to assess in TBI)
• Meningism (unreliable in intubated patients)
• Purulent CSF

CSF Analysis for EVD-Related Ventriculitis:

Common Pathogens:

• Coagulase-negative Staphylococci (most common, 30-60%)
• Staphylococcus aureus (including MRSA, 15-25%)
• Gram-negative bacilli (Pseudomonas, Acinetobacter, Enterobacter, 20-30%)
• Enterococci (5-10%)
• Candida species (rare, immunocompromised)

Treatment (PMID: 28234143):

Intrathecal Antibiotics Indication:

• Failure of IV therapy alone
• Resistant organisms
• Poor CSF penetration of systemic antibiotics

EVD Management During Ventriculitis:

• Do NOT remove EVD immediately if draining well and infection is responding
• Consider EVD exchange if persistent infection
• Continue CSF drainage as therapeutic (removes infected fluid)
• Daily CSF sampling until culture-negative

Duration of Treatment:

• 10-14 days for uncomplicated ventriculitis
• 21 days for complicated infections (abscess, resistant organisms)
• Serial CSF cultures to confirm clearance

---

ICP Management

Brain Trauma Foundation Guidelines (BTF 2024)

Key Recommendations (PMID: 27654279):

Changes from BTF 4th Edition (2016):

• ICP threshold changed from 20 to 22 mmHg (post-hoc BEST-TRIP analysis)
• Greater emphasis on multimodality monitoring
• Updated decompressive craniectomy evidence (RESCUE-ICP)

Tiered Approach to ICP Management

Tier 0: Prevention of ICP Elevation

Tier 1: First-Line ICP Therapy

Mannitol vs Hypertonic Saline (PMID: 32178337):

Meta-analysis (PMID: 32178337): Hypertonic saline may be more effective than mannitol for ICP reduction, but no mortality difference demonstrated.

Tier 2: Second-Line ICP Therapy

Moderate Hyperventilation Cautions:

• Causes cerebral vasoconstriction → reduced CBF
• Risk of ischemia (jugular venous saturation monitoring recommended)
• Use only as temporizing measure (minutes to hours)
• Target SjvO2 >55% or PbtO2 >20 mmHg

Tier 3: Salvage Therapies

Decompressive Craniectomy

DECRA Trial (2011) (PMID: 21434843):

• Population: Diffuse TBI with refractory ICP >20 mmHg for 15+ min
• Intervention: Bifrontal craniectomy vs medical management
• Outcome: Lower ICP but worse functional outcomes (unfavorable GOS-E 70% vs 51%)
• Criticism: Early timing, low ICP threshold, diffuse injury only

RESCUE-ICP Trial (2016) (PMID: 27178479):

• Population: TBI with ICP >25 mmHg for 1-12 hours despite Tier 2 therapy
• Intervention: Decompressive craniectomy vs medical management (including barbiturates)
• Outcome: Reduced mortality (26.9% vs 48.9%), but increased vegetative state (8.5% vs 2.1%)
• Conclusion: DC saves lives but with functional outcome trade-offs

Current Approach:

• Reserve for refractory ICP despite maximal medical therapy
• Informed discussion with family regarding outcomes
• Consider patient factors (age, comorbidities, pre-injury function)
• Unilateral hemicraniectomy preferred for focal lesions

Barbiturate Coma

Indications:

• Refractory intracranial hypertension
• Tier 3 therapy after CSF drainage, osmotherapy, and sedation optimization
• Alternative or bridge to decompressive craniectomy

Protocol (PMID: 25320101):

• Thiopentone: Loading 5-10 mg/kg IV, maintenance 3-5 mg/kg/hr
• Pentobarbital: Loading 10-25 mg/kg, maintenance 1-3 mg/kg/hr
• Target: Burst suppression on EEG (3-5 bursts/min) OR serum level 30-50 mg/L

Monitoring During Barbiturate Coma:

• Continuous EEG (target burst suppression)
• Hemodynamics (profound hypotension common, requires vasopressors)
• Cardiac function (myocardial depression)
• Temperature (hypothermia common)
• Ileus (common)

Complications:

• Cardiovascular: Hypotension (30-50% require vasopressors), myocardial depression
• Respiratory: Prolonged ventilation
• Infectious: Increased pneumonia, sepsis (immunosuppression)
• Metabolic: Hypothermia, electrolyte abnormalities
• Pharmacokinetic: Very long half-life (24-48h), prolonged emergence

Evidence (PMID: 25320101):

• Reduces ICP effectively
• No proven mortality benefit in RCTs
• Cochrane review: Insufficient evidence to recommend routine use

Therapeutic Hypothermia for TBI

Evidence Against Routine Hypothermia:

Eurotherm3235 Trial (2015) (PMID: 26444221):

• Hypothermia (32-35°C) for ICP control in TBI
• Stopped early for harm: Worse outcomes with hypothermia
• Increased mortality (OR 1.45, 95% CI 1.01-2.10)

POLAR Trial (2018) (PMID: 30318387):

• Prophylactic hypothermia (33°C for 72h) in severe TBI
• No benefit on functional outcome (GOS-E)
• No mortality difference

Current Recommendation:

• NOT recommended as first-line therapy for ICP control
• May have role in specific circumstances (refractory ICP, cardiac arrest with TBI)
• Avoid hyperthermia (aggressive fever control essential)

---

Multimodality Monitoring

Cerebral Oxygenation Monitoring

Brain Tissue Oxygen Tension (PbtO2) (PMID: 27267325):

BOOST-II Trial:

• Compared ICP-only vs ICP + PbtO2-guided therapy
• PbtO2 target: >20 mmHg
• Trend toward reduced mortality with PbtO2 guidance (25% vs 34%, p=0.16)
• Phase 3 trial (BOOST-3) ongoing

Normal Values:

• PbtO2 normal: 25-35 mmHg
• PbtO2 critical threshold: <20 mmHg (brain hypoxia)
• PbtO2 <15 mmHg: Severe hypoxia, associated with poor outcome

Interventions for Low PbtO2:

• Increase FiO2
• Increase CPP (if autoregulation intact)
• Transfuse if Hb <9-10 g/dL
• Reduce CMRO2 (sedation, temperature control)
• Treat intracranial hypertension

Jugular Venous Oxygen Saturation (SjvO2):

Limitations:

• Global measurement (may miss focal ischemia)
• Requires jugular bulb catheterization
• Artifacts common (catheter position, contamination)

Cerebral Microdialysis

Principle: Samples extracellular fluid to measure metabolites

Key Metabolites:

Clinical Use:

• Research and specialized centers
• Not routine clinical practice
• Helps distinguish ischemia from mitochondrial dysfunction

Continuous EEG Monitoring

Indications in Neurotrauma:

• Unexplained decreased consciousness
• Detection of non-convulsive seizures (15-25% of TBI patients)
• Monitoring depth of barbiturate coma
• Prognostication

Seizure Burden:

• Non-convulsive status epilepticus associated with poor outcome
• Treatment with antiepileptic drugs if seizures detected

---

Australian/NZ Context

ANZICS-CORE Traumatic Brain Injury Statement

Key Recommendations:

1. ICP monitoring in severe TBI (GCS ≤8) with abnormal CT
2. Protocolized ICP management with tiered approach
3. Target ICP <22 mmHg and CPP 60-70 mmHg
4. EVD preferred when feasible for combined monitoring and drainage
5. Multimodality monitoring encouraged in severe TBI

Retrieval Medicine Considerations

Aeromedical Transfer:

• Altitude effects: Reduced barometric pressure may affect ICP monitoring
• Pre-transfer optimization: Sedation, ICP control, secure EVD
• Fixed-wing vs rotary: Fixed-wing preferred for long distances, pressurized cabin
• Portable ICP monitors available for retrieval

State Retrieval Services:

• NSW: Adult Retrieval and Aeromedical Service (AMRAS), NETS for paediatric
• Victoria: Adult Retrieval Victoria (ARV)
• Queensland: Retrieval Services Queensland (RSQ)
• Western Australia: RFDS, Royal Perth Hospital Retrieval
• South Australia: MedSTAR
• New Zealand: National Patient Transfer Services

Pre-Transfer Checklist for TBI:

• Airway secured (intubated)
• Adequate sedation and analgesia
• ICP control achieved (if monitored)
• EVD clamped and secured (if in situ)
• Blood pressure targets documented
• Anticonvulsant prophylaxis
• Documentation of GCS, pupils, imaging
• Neurosurgical consultation completed

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Peoples:

• 2-3× higher rates of traumatic brain injury (PMID: 26413143)
• Higher rates of assault-related and transport-related TBI
• More remote presentations with delayed neurosurgical access
• Cultural considerations in family meetings and goals of care discussions

Culturally Safe Care:

• Involve Aboriginal Health Workers/Liaison Officers in all discussions
• Extended family involvement in decision-making
• Consider cultural obligations and community connections
• Sensitivity around brain injury in cultural context
• Language and health literacy considerations
• Discharge planning to community with support services

Māori Health (New Zealand):

• 1.5-2× higher TBI rates
• Whānau (extended family) involvement essential
• Māori Health Workers as key support
• Consider tikanga (customs) in care delivery
• Awareness of healthcare access barriers in rural areas

---

Prognosis & Outcomes

Prognostic Factors in TBI

Clinical Predictors (PMID: 29158417):

IMPACT and CRASH Prognostic Models (PMID: 29158417):

• Validated models for TBI outcome prediction
• Variables: Age, GCS, pupils, CT findings, hypotension, hypoxia
• Available as online calculators
• Useful for family counseling and clinical decision-making

Outcome Measures

Glasgow Outcome Scale Extended (GOS-E):

Favorable Outcome: GOS-E 5-8 (moderate disability or better) Unfavorable Outcome: GOS-E 1-4 (death, vegetative state, severe disability)

Long-Term Outcomes

Severe TBI Survivors:

• Return to work: 30-50% at 1 year
• Cognitive impairment: 60-70%
• Behavioral changes: 40-60%
• Post-traumatic epilepsy: 10-20%
• Depression: 25-50%

---

SAQ Practice Questions

SAQ 1: ICP Physiology and Monitoring (20 marks)

Question: A 25-year-old male is brought to your ICU following a motor vehicle collision. His initial GCS was 6 (E1V2M3). CT brain shows bilateral frontal contusions with subarachnoid hemorrhage and early cerebral edema. An external ventricular drain (EVD) has been inserted by neurosurgery.

a) Describe the Monro-Kellie doctrine and its clinical relevance in this patient. (5 marks)

b) Explain the components of the intracranial pressure waveform and their clinical significance. (5 marks)

c) Compare and contrast the advantages and disadvantages of EVD versus intraparenchymal ICP monitoring. (5 marks)

d) The patient's ICP reading suddenly rises to 35 mmHg with dampening of the waveform. Outline your systematic approach to assessment and management. (5 marks)

---

Model Answer:

(a) Monro-Kellie Doctrine (5 marks)

The Monro-Kellie doctrine states that the cranium is a rigid container with fixed total volume (~1,400-1,700 mL). The three intracranial compartments are:

• Brain parenchyma: ~80% (1,200-1,400 mL)
• Blood (arterial + venous): ~10% (100-150 mL)
• Cerebrospinal fluid: ~10% (100-150 mL)

Key principle: The sum of these volumes is constant. An increase in one compartment must be compensated by a decrease in another, or intracranial pressure will rise.

Compensatory mechanisms (in order of activation):

1. CSF displacement from intracranial to spinal subarachnoid space
2. Reduction in intracranial venous blood volume (compression of venous sinuses)
3. Limited brain parenchymal compression

Clinical relevance in this patient:

• Bilateral contusions and SAH represent space-occupying lesions increasing brain volume
• Cerebral edema (cytotoxic and vasogenic) further increases brain compartment
• Compensatory mechanisms will initially buffer these changes
• Once exhausted, small volume increases cause exponential ICP rises (steep portion of pressure-volume curve)
• This patient is at high risk for intracranial hypertension

(b) ICP Waveform Components (5 marks)

The ICP waveform is a modified arterial waveform transmitted through intracranial contents. Three components:

P1 (Percussion wave):

• Origin: Arterial pulsation transmitted through choroid plexus
• Normally the highest peak (sharp, narrow)
• Reflects systemic arterial pressure

P2 (Tidal wave):

• Origin: Intracranial compliance/recoil
• Normally lower than P1, rounded
• Key clinical indicator: Height reflects intracranial compliance

P3 (Dicrotic wave):

• Origin: Venous pulsation (aortic valve closure)
• Lowest of the three, tapered
• May have preceding dicrotic notch

Clinical significance:

• Normal pattern: P1 > P2 > P3 - indicates good intracranial compliance
• Reduced compliance: P2 > P1, waveform becomes more rounded/sinusoidal
• When P2 > P1: Warning of impending decompensation - small volume changes will cause large pressure increases
• Lundberg A waves (plateau waves): Sustained elevations 50-100 mmHg lasting 5-20 minutes indicate exhausted compliance and impaired autoregulation

(c) EVD vs Intraparenchymal Monitoring (5 marks)

Summary: EVD preferred when ventricular cannulation possible and CSF drainage needed. Intraparenchymal monitor appropriate when ventricles small, quick insertion required, or as adjunct to EVD.

(d) Approach to Sudden ICP Rise with Dampened Waveform (5 marks)

Immediate assessment (ABCDE approach):

• A/B: Confirm ETT position, adequate ventilation (avoid hypercapnia)
• C: Check MAP, calculate CPP, ensure adequate BP
• D: Pupils, GCS, focal signs (if assessable)
• E: Temperature, glucose, signs of seizure

Systematic EVD troubleshooting:

1. Check transducer position: Confirm zeroed at tragus level
2. Check connections: All connections intact, no air bubbles
3. Check catheter: Look for kinking, blood clot in tubing
4. Flush attempt: Gentle flush with sterile saline (if no contraindication)
5. Lower drainage bag: Temporarily lower to see if CSF drains
6. Check patient position: Head of bed 30°, midline position

Systematic evaluation for ICP causes:

• Systemic: Hypoxia (SpO2, PaO2), hypercapnia (PaCO2), fever, hyponatremia, seizure
• Intracranial: New hematoma, worsening edema, hydrocephalus, catheter malposition

Immediate management:

• If true ICP elevation: CSF drainage (open EVD)
• Osmotherapy: Mannitol 0.5-1 g/kg or HTS 30 mL 23.4% (3% 150 mL)
• Deepen sedation: Propofol bolus
• Brief hyperventilation if impending herniation: Target PaCO2 28-30 mmHg temporarily
• Urgent CT brain if no response or new focal signs

Communication:

• Notify neurosurgery for possible EVD revision or surgical intervention
• Escalation to Tier 2/3 therapy if refractory

---

SAQ 2: ICP Management and Evidence (20 marks)

Question: A 45-year-old female is admitted to ICU following a fall from a horse. Initial GCS was 7 (E2V1M4). CT shows a left temporal contusion with 8 mm midline shift and effaced basal cisterns. An intraparenchymal ICP monitor shows ICP 28 mmHg. CPP is 55 mmHg.

a) Outline the evidence-based thresholds for ICP and CPP management according to Brain Trauma Foundation Guidelines. Explain the rationale for these thresholds. (5 marks)

b) Describe your tiered approach to managing this patient's intracranial hypertension. (6 marks)

c) Critically evaluate the BEST-TRIP trial and explain why ICP monitoring remains standard of care despite its findings. (5 marks)

d) The patient's ICP remains 32-40 mmHg despite Tier 1 and 2 therapies. Discuss the evidence for decompressive craniectomy and the considerations in this case. (4 marks)

---

Model Answer:

(a) BTF Thresholds and Rationale (5 marks)

Brain Trauma Foundation Guidelines (2024) Recommendations:

ICP Threshold: >22 mmHg (Level IIB evidence)

• Changed from 20 mmHg in previous editions
• Based on post-hoc analysis of BEST-TRIP and outcome data
• ICP >22 mmHg independently associated with increased mortality
• Treatment should be initiated when ICP exceeds 22 mmHg for more than 5 minutes

CPP Target: 60-70 mmHg (Level IIB evidence)

Rationale for thresholds:

• CPP minimum 60 mmHg: Below this, cerebral blood flow becomes critically low

  • Studies show CPP <50 mmHg associated with ischemia on PbtO2 monitoring
  • Mortality increases significantly below 60 mmHg

• CPP maximum 70 mmHg: Avoid aggressive CPP augmentation above this

  • "Robertson et al. (2009): CPP >70 mmHg associated with 5× increased ARDS risk"
  • No additional benefit in cerebral perfusion
  • Vasopressor-related complications (pulmonary edema, myocardial dysfunction)

• Avoid CPP <50 mmHg: Level III evidence

  • Associated with significantly worse outcomes
  • Should trigger immediate intervention

In this patient: CPP = MAP - ICP = (55 + 28) - 28 = 55 mmHg (approximately, assuming MAP ~83 if CPP 55 with ICP 28) This is below target; need to both reduce ICP and optimize MAP.

(b) Tiered ICP Management (6 marks)

Tier 0: Prevention (ensure these are optimized first)

• Head elevation 30°, midline position
• Adequate sedation (propofol + opioid, target RASS -4 to -5)
• Normothermia (target 36-37°C, active cooling if febrile)
• Normocapnia (PaCO2 35-40 mmHg)
• Avoid hypoxia (PaO2 >60 mmHg, SpO2 >94%)
• Avoid hyponatremia (Na+ 140-145 mmol/L)
• Euglycemia (6-10 mmol/L)
• Seizure prophylaxis (levetiracetam 500-1000 mg BD)
• Avoid venous obstruction (loose ETT tie, avoid IJ lines if possible)

Tier 1: First-line therapy

• CSF drainage: Insert EVD (intraparenchymal monitor cannot drain)
  • This patient should have EVD for therapeutic drainage
• Osmotherapy first line:
  • Mannitol 0.5-1 g/kg IV (e.g., 100 mL 20%) OR
  • Hypertonic saline 30 mL 23.4% or 150 mL 3%
  • Monitor serum osmolality (<320 mOsm/L for mannitol) and Na+ (<160 mmol/L for HTS)
• Optimize CPP: Target MAP to achieve CPP 60-70 mmHg
  • May require noradrenaline infusion

Tier 2: Second-line therapy (if Tier 1 fails)

• Repeat osmotherapy: Alternate agents, check for response
• Moderate hyperventilation: PaCO2 28-32 mmHg temporarily
  • Monitor for ischemia (SjvO2 >55%, PbtO2 >20 mmHg if available)
• Neuromuscular blockade: Reduces intrathoracic pressure, prevents coughing
• Deepen sedation: Higher-dose propofol

Tier 3: Salvage therapy (refractory intracranial hypertension)

• Decompressive craniectomy: Unilateral for focal lesion (as in this patient)
• Barbiturate coma: Thiopentone loading + maintenance
• Therapeutic hypothermia: Limited evidence, generally NOT recommended

(c) Critical Evaluation of BEST-TRIP (5 marks)

BEST-TRIP Trial (2012) (PMID: 23234472):

• Setting: Bolivia, Ecuador
• Population: 324 patients with severe TBI (GCS 3-8)
• Intervention: ICP monitoring-based protocol vs clinical/imaging-based protocol
• Primary outcome: Composite of mortality and GOS-E at 6 months
• Result: No difference in primary outcome (ICP group 39% vs imaging group 41% favorable)

Why ICP monitoring remains standard of care despite BEST-TRIP:

1. Both groups received aggressive ICP therapy

   • Imaging-based group received similar interventions (hyperosmolar therapy, surgery)
   • Difference was in monitoring, not treatment intensity
   • Cannot conclude that ICP control doesn't matter

2. Study limitations

   • Developing country setting (may not apply to high-resource environments)
   • Limited access to multimodality monitoring
   • Clinical expertise may differ between settings
   • Power to detect small but clinically important differences may have been insufficient

3. ICP monitoring provides additional value

   • Continuous real-time monitoring vs intermittent imaging
   • Earlier detection of deterioration
   • Guides titration of therapy
   • Enables CSF drainage through EVD
   • Part of multimodality monitoring strategy

4. Post-hoc analyses

   • Patients with better ICP control had better outcomes in both groups
   • Supports the importance of ICP as a therapeutic target

5. Current interpretation

   • BEST-TRIP shows clinical assessment can guide therapy when monitoring unavailable
   • Does NOT show that ICP monitoring is harmful or useless
   • Standard of care in developed settings remains ICP monitoring-guided therapy

(d) Decompressive Craniectomy Evidence and Considerations (4 marks)

Evidence:

DECRA Trial (2011) (PMID: 21434843):

• Bifrontal craniectomy for diffuse TBI with refractory ICP >20 mmHg for 15+ minutes
• Result: Lower ICP but worse functional outcomes (unfavorable GOS-E 70% vs 51%)
• Limitation: Early intervention, low threshold, diffuse injury only

RESCUE-ICP Trial (2016) (PMID: 27178479):

• Craniectomy vs maximal medical management for ICP >25 mmHg despite Tier 2 therapy
• Result: Reduced mortality (26.9% vs 48.9%) but increased vegetative state (8.5% vs 2.1%)
• At 12 months: Similar rates of moderate disability or better

Considerations in this case:

• Focal lesion with mass effect: Unilateral (left) craniectomy appropriate
• Age 45: Middle-aged, reasonable baseline function expected
• 8 mm midline shift: Significant mass effect favoring surgery
• Contusion may be evacuated: Combined craniectomy and contusion evacuation

Decision-making:

• Discuss with neurosurgery
• Family meeting regarding expectations:
  • Surgery may save life but increase risk of severe disability
  • Alternative is continued medical management with risk of death from refractory ICP
• Consider patient's pre-morbid wishes if known
• Cultural and family considerations

Recommendation: Given focal pathology, age, and refractory ICP, decompressive craniectomy with contusion evacuation is reasonable. Family must understand outcome trade-offs.

---

Viva Scenarios

Viva 1: ICP Waveform Interpretation and EVD Management

Opening Scenario: The examiner shows you an ICP trace from a patient with severe TBI. The trace shows a mean ICP of 18 mmHg with waveforms where P2 is clearly higher than P1.

---

Examiner: "Describe what you see on this ICP trace and explain its significance."

Candidate: "Thank you for showing me this trace. I can see a continuous ICP recording with a mean pressure of 18 mmHg. Looking at the individual waveforms, I notice that the P2 wave, or tidal wave, is higher than the P1 wave, or percussion wave. This pattern indicates reduced intracranial compliance."

Examiner: "Explain the physiological basis for this interpretation."

Candidate: "The ICP waveform has three components reflecting the cardiac cycle. P1, the percussion wave, represents arterial pulsation transmitted through the choroid plexus. P2, the tidal wave, represents the recoil of the intracranial contents and reflects compliance. P3, the dicrotic wave, represents venous pulsation.

In normal conditions with good compliance, P1 is the highest peak because it represents the direct arterial pulse. P2 is lower because the compliant system absorbs the pressure wave. However, when compliance is reduced, the intracranial contents cannot absorb the pressure wave effectively, so P2 becomes elevated.

When P2 exceeds P1, it indicates the patient is on the steep portion of the pressure-volume curve. Small volume changes will now cause large pressure increases. Even though the mean ICP of 18 mmHg is below the treatment threshold of 22 mmHg, this waveform pattern is a warning sign."

Examiner: "What are Lundberg waves and their clinical significance?"

Candidate: "Lundberg waves are slow oscillations in ICP, classified into three types by Nils Lundberg in 1960.

A waves, or plateau waves, are the most clinically significant. They are pathological elevations of ICP to 50-100 mmHg lasting 5-20 minutes. They occur due to a vicious cycle where ICP rises, CPP falls, autoregulatory vasodilation occurs to maintain blood flow, this increases cerebral blood volume, which further raises ICP. They indicate exhausted compliance and impaired autoregulation, requiring immediate intervention.

B waves are oscillations of 10-20 mmHg at a frequency of 0.5-2 per minute. They are related to respiratory and vasomotor activity and may be physiological or early pathological.

C waves are small amplitude waves at 4-8 per minute related to the arterial waveform. They are of limited clinical significance."

Examiner: "The patient has an EVD in situ. Describe how you would zero and level the EVD for accurate ICP monitoring."

Candidate: "Accurate ICP monitoring requires proper zeroing and leveling of the EVD system.

For zeroing, I would open the transducer to atmosphere while closed to the patient, then press the zero button on the monitor. This establishes atmospheric pressure as the zero reference point.

For leveling, the transducer must be at the level of the foramen of Monro. The external anatomical landmark for this is the tragus, or external auditory meatus. I would align the transducer at this level using a spirit level or laser leveling system.

If the patient's head position changes, the transducer must be re-leveled. A 1 cm discrepancy causes approximately 0.77 mmHg error. When the patient is nursed head-up at 30 degrees, the tragus remains the reference point but should be re-confirmed.

Similarly, the drainage height is set relative to this reference point. A typical initial setting is 10-15 cmH2O above the tragus."

Examiner: "The nurse reports the ICP suddenly dropped to 2 mmHg with loss of waveform. What are your considerations?"

Candidate: "A sudden drop in ICP to very low values with loss of waveform is concerning and requires immediate assessment. The main considerations are:

First, I would consider technical issues: Is the EVD disconnected or open to drainage? Is there air in the system? Has the transducer moved or become disconnected?

Second, I would consider over-drainage. If the drainage bag has been placed too low relative to the tragus, excessive CSF drainage can occur, causing intracranial hypotension.

Third, I would consider catheter malposition. The catheter may have migrated out of the ventricle or become obstructed by brain tissue rather than CSF.

Fourth, I would consider catastrophic loss of brain function, though this is rare and would be accompanied by other clinical signs.

My immediate actions would be to check all connections, verify transducer position, check drainage bag height, and assess the patient clinically including pupillary examination and any change in neurological status. I would also review any recent interventions such as turning the patient.

If over-drainage is suspected, I would raise the drainage height, clamp the EVD temporarily, and position the patient head-down if safe to do so. If the problem persists, an urgent CT may be needed to check catheter position and rule out new pathology."

---

Viva 2: CPP Optimization and BEST-TRIP Trial

Opening Scenario: "You are caring for a 30-year-old male with severe TBI. His EVD shows ICP 24 mmHg, and MAP is 75 mmHg. He is sedated with propofol and fentanyl, and his head is elevated at 30 degrees."

---

Examiner: "Calculate the CPP and comment on whether the current values are acceptable."

Candidate: "The CPP is calculated as MAP minus ICP, which is 75 minus 24, giving a CPP of 51 mmHg.

According to the Brain Trauma Foundation 2024 guidelines, the target CPP is 60-70 mmHg, with a minimum of 60 mmHg and avoidance of values below 50 mmHg. This patient's CPP of 51 mmHg is below target but just above the critical threshold.

Additionally, the ICP of 24 mmHg is above the treatment threshold of 22 mmHg. So both parameters need optimization."

Examiner: "How would you approach optimizing both ICP and CPP in this patient?"

Candidate: "I would take a systematic approach addressing both ICP reduction and CPP augmentation.

First, I would ensure Tier 0 measures are optimized: head elevation at 30 degrees with midline position, adequate sedation depth, normothermia, normocapnia with PaCO2 35-40 mmHg, and checking for any venous obstruction.

For ICP reduction, I would open the EVD to drain CSF to a target ICP below 22 mmHg. I would also administer osmotherapy, either mannitol 0.5 g/kg or 30 mL of 23.4% hypertonic saline, depending on serum sodium and osmolality.

For CPP augmentation, once ICP is reduced, I would aim for a MAP that achieves CPP 60-70 mmHg. If ICP is 20 mmHg, I would target MAP 80-90 mmHg, which may require noradrenaline infusion.

However, I would avoid pushing CPP above 70 mmHg because the BTF guidelines warn against this due to increased risk of ARDS. Robertson's study showed a 5-fold increase in ARDS risk with CPP augmentation beyond 70 mmHg."

Examiner: "Tell me about the BEST-TRIP trial. What were the findings and how should we interpret them?"

Candidate: "The BEST-TRIP trial was published in 2012 and conducted in Bolivia and Ecuador. It enrolled 324 patients with severe traumatic brain injury and randomized them to either ICP monitoring-guided management or a protocol based on clinical and imaging findings without ICP monitoring.

The primary outcome was a composite of survival time, impaired consciousness at 6 months, and functional status. The trial found no significant difference between the groups, with 39% having favorable outcomes in the ICP monitoring group compared to 41% in the imaging-based group.

However, this trial should be interpreted carefully and does not mean ICP monitoring is unnecessary.

First, both groups received aggressive ICP-directed therapy. The imaging-based group received similar interventions including osmotherapy and surgical decompression based on clinical and radiological signs. The trial compared monitoring strategies, not treatment strategies.

Second, the setting was resource-limited, which may not translate to well-resourced ICUs where multimodality monitoring and rapid neurosurgical intervention are available.

Third, post-hoc analysis showed that patients with better ICP control had better outcomes regardless of which group they were in, suggesting ICP as a therapeutic target remains valid.

Fourth, ICP monitoring provides continuous real-time data that allows titration of therapy and early detection of deterioration before clinical signs emerge.

In Australia and New Zealand, ICP monitoring remains standard of care for severe TBI, and ANZICS-CORE guidelines support its use."

Examiner: "A colleague suggests targeting CPP >80 mmHg to ensure adequate cerebral perfusion. How would you respond?"

Candidate: "I would respectfully discuss the evidence against aggressive CPP augmentation.

The BTF guidelines specifically recommend avoiding CPP above 70 mmHg, citing Level IIB evidence. The landmark study by Robertson and colleagues in 2009 demonstrated that targeting CPP greater than 70 mmHg was associated with a 5-fold increase in ARDS compared to a lower CPP target.

The mechanism relates to the need for vasopressors and intravenous fluids to achieve higher MAP. This leads to increased pulmonary capillary hydrostatic pressure and capillary leak, resulting in acute lung injury.

Additionally, in patients with impaired autoregulation, excessive CPP may cause hyperemia and worsening cerebral edema rather than improved perfusion.

A more individualized approach using the pressure reactivity index, or PRx, can identify the optimal CPP for each patient. This is the CPP at which autoregulation is most intact, typically where PRx is most negative.

I would recommend targeting CPP 60-70 mmHg as per guidelines, monitoring for signs of cerebral ischemia such as low SjvO2 or PbtO2 if available, and considering PRx-guided optimization in centers with this capability."

---

Hot Case Scenario

Severe TBI with EVD and Rising ICP

Scenario: You are asked to review a 28-year-old male in the neurosurgical ICU. He was admitted 3 days ago following a motorcycle accident with severe TBI. Initial GCS was 5 (E1V1M3). CT showed bifrontal contusions with subarachnoid hemorrhage. An EVD was inserted on admission.

Current status:

• Intubated and ventilated on SIMV, FiO2 0.4, PEEP 8
• Sedated with propofol 200 mg/hr and fentanyl 200 mcg/hr
• EVD in situ, draining at 15 cmH2O above tragus
• ICP over last 2 hours has increased from 18 to 28 mmHg
• MAP 82 mmHg, HR 65 bpm
• Temperature 38.2°C
• Last serum sodium 148 mmol/L, osmolality 305 mOsm/L

---

Assessment Approach:

A - Airway:

• ETT 8.0 mm oral, 22 cm at lips, secured
• Check position, cuff pressure (20-30 cmH2O)
• No leak audible

B - Breathing:

• Ventilator: SIMV, FiO2 0.4, PEEP 8, Vt 500 mL, RR 14
• SpO2 98%, EtCO2 38 mmHg
• Chest clear bilaterally
• ABG: pH 7.38, PaCO2 40, PaO2 120, BE 0, Lactate 1.2

C - Circulation:

• MAP 82 mmHg (IBP), HR 65 bpm sinus
• CPP = 82 - 28 = 54 mmHg (below target)
• Noradrenaline 10 mcg/min
• JVP not elevated
• Cap refill <2 sec

D - Disability:

• Sedation: Propofol 200 mg/hr, Fentanyl 200 mcg/hr
• GCS: E1VtM2 (decorticate posturing to pain through sedation)
• Pupils: Right 3mm reactive, Left 4mm sluggish
• ICP: 28 mmHg, waveform shows P2 > P1
• EVD: Draining clear CSF, 8 mL/hr over last 4 hours

E - Exposure/Environment:

• Temperature 38.2°C (febrile)
• Glucose 8.2 mmol/L
• No seizure activity

---

Key Findings:

1. Rising ICP to 28 mmHg (above threshold of 22 mmHg)
2. CPP 54 mmHg (below target 60-70 mmHg)
3. Asymmetric pupils with left sluggish (possible early uncal herniation)
4. P2 > P1 waveform (reduced compliance)
5. Fever (potential cause of ICP rise, or sign of infection)
6. Already on modest sedation and noradrenaline

---

Management Discussion:

Immediate Actions:

1. Optimize EVD drainage - lower to 10 cmH2O if safe
2. Increase sedation - propofol bolus 50-100 mg
3. Osmotherapy - HTS 30 mL 23.4% or mannitol 0.5 g/kg
4. Increase noradrenaline to achieve CPP 60-70 mmHg
5. Active cooling to <37.5°C

Investigation:

• Urgent CT brain - rule out new hemorrhage, worsening edema, hydrocephalus
• CSF sample - rule out ventriculitis (fever, elevated ICP)
• Blood cultures, urine culture - septic workup

Escalation if No Response:

• Tier 2: Moderate hyperventilation (PaCO2 30-32), NMB
• Tier 3: Neurosurgical discussion for decompressive craniectomy, barbiturate coma

Communication:

• Neurosurgery: Discuss surgical options, CT findings
• Family: Update on deterioration, potential need for surgery
• Document clearly in notes